Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

China · Delayed Price · Currency is CNY

73.77

-1.36 (-1.81%)

At close: Mar 2, 2026

-12.51% (1Y)

Market Cap	30.11B
Revenue (ttm)	3.70B
Net Income (ttm)	1.04B
Shares Out	408.19M
EPS (ttm)	2.55
PE Ratio	28.93
Forward PE	20.61
Dividend	0.62 (0.83%)
Ex-Dividend Date	May 9, 2025

Volume	2,647,508
Average Volume	2,335,351
Open	74.82
Previous Close	75.13
Day's Range	72.45 - 74.85
52-Week Range	67.96 - 93.52
Beta	-0.17
RSI	51.02
Earnings Date	Mar 27, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1996

Employees 2,685

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688278

Full Company Profile

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.04 billion, an increase of 25.39%.

Financial Statements

News

There is no news available yet.